SOPHiA GENETICS (SOPH)
(Delayed Data from NSDQ)
$4.45 USD
-0.04 (-0.89%)
Updated Aug 2, 2024 03:59 PM ET
After-Market: $4.45 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SOPH 4.45 -0.04(-0.89%)
Will SOPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SOPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SOPH
Fulgent Genetics, Inc. (FLGT) Beats Q2 Earnings and Revenue Estimates
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
SOPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think SOPHiA GENETICS (SOPH) Could Surge 64.95%: Read This Before Placing a Bet
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Misses Revenue Estimates
SOPHiA GENETICS SA (SOPH) Reports Q1 Loss, Tops Revenue Estimates
Other News for SOPH
SOPHiA GENETICS Announces L'hopital Universitaire Avicenne is Live on SOPHiA DDM?
SOPHIA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix
Sophia Genetics announces expanded relationship with OncoHelix
Sophia Genetics expands relationship with OncoHelix
SOPHiA GENETICS Announces Expanded Relationship with Canada-Based OncoHelix